United States was the largest of Bristol Myers Squibb Co’s 3 reported lines in fiscal 2025, at $99.84B — 69% of $144.58B.
| Geography | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $94.50B | $93.63B | $102.32B | $99.84B | |||||||||||
| International | $41.48B | $39.29B | $39.60B | $41.48B | |||||||||||
| Salesrevenuenet | — | — | — | — | |||||||||||
| Europe | — | — | — | — | |||||||||||
| European Union | — | — | — | — | |||||||||||
| Rest Of World | — | — | — | — | |||||||||||
| Other | $2.50B | $2.10B | $2.99B | $3.26B | |||||||||||
| Other Region | — | — | — | — | |||||||||||
| Total | $138.48B | $135.02B | $144.90B | $144.58B |
In fiscal 2025, which ended December 31, 2025, the 3 regions Bristol Myers Squibb Co reported in this breakdown added up to $144.58B. That was down 0.2% from $144.90B in fiscal 2024. United States was the largest region, at $99.84B or 69.1% of the total, followed by International ($41.48B, 28.7%) and Other ($3.26B, 2.3%). Together, the two largest regions made up 97.7% of this total.
Compared with fiscal 2024, Other grew the fastest, rising 9.1% to $3.26B. United States fell the most, down 2.4% to $99.84B. Over fiscal 2022 to 2025, revenue across these regions went from $138.48B to $144.58B, a compound annual growth rate of 1.4%. United States' share of the total rose from 68.2% to 69.1% over the same years.
The table also keeps 5 regions that Bristol Myers Squibb Co no longer reports, so earlier years can still be read on their original basis; use "Show 5 discontinued" beneath the table to see them. This breakdown covers 15 fiscal years between 2009 and 2025, as reported in Bristol Myers Squibb Co's annual filings.
Ono was the largest of Bristol Myers Squibb Co’s 2 reported lines in fiscal 2014, at $339.00M — 53% of $645.00M.
| Products and Services | FY 2012 | FY 2013 | FY 2014 |
|---|---|---|---|
| Alliance Partners | $29.62B | $24.66B | — |
| Otsuka | — | $10.15B | — |
| Sanofi | $9.15B | $1.47B | $306.00M |
| Astrazeneca | $2.92B | — | — |
| Pfizer | — | $438.00M | — |
| Ono | — | $135.00M | $339.00M |
| Valeant | $30.00M | $159.00M | — |
| Total | $41.71B | $37.01B | $645.00M |
In fiscal 2014, which ended December 31, 2014, the 2 revenue lines Bristol Myers Squibb Co reported in this breakdown added up to $645.00M. The revenue lines reported changed from fiscal 2013, so the total is not directly comparable with the $37.01B reported that year. Ono was the largest revenue line, at $339.00M or 52.6% of the total, followed by Sanofi ($306.00M, 47.4%).
Compared with fiscal 2013, Ono grew the fastest, rising 151.1% to $339.00M. Sanofi fell the most, down 79.1% to $306.00M. Because revenue lines were added or dropped between the two years, part of this reflects how Bristol Myers Squibb Co regrouped its reporting.
Ono was first reported as a separate revenue line in fiscal 2013. The table also keeps 5 revenue lines that Bristol Myers Squibb Co no longer reports, so earlier years can still be read on their original basis; use "Show 5 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2012 to 2014, as reported in Bristol Myers Squibb Co's annual filings.
Eliquis was the largest of Bristol Myers Squibb Co’s 11 reported lines in fiscal 2019, at $23.79B — 30% of $78.44B.
| Product and Service | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Opdivo | $11.32B | $14.84B | $20.21B | $21.61B | ||||||
| Salesrevenuenet | — | — | — | — | ||||||
| Eliquis | $10.03B | $14.62B | $19.31B | $23.79B | ||||||
| Mature & Other Brands | — | — | — | $6.86B | ||||||
| Mature Products & All Other | $6.81B | $11.84B | $7.07B | — | ||||||
| Abilify | — | — | — | — | ||||||
| Orencia | $6.80B | $7.44B | $8.13B | $8.93B | ||||||
| Sprycel | $5.47B | $6.02B | $6.00B | $6.33B | ||||||
| Hepatitis C Portfolio | $4.73B | $1.22B | — | — | ||||||
| Avapro, Avalide, & Plavix | $714.00M | $702.00M | — | — | ||||||
| Baraclude | $3.58B | $3.16B | $2.23B | — | ||||||
| Yervoy | $3.16B | $3.73B | $3.99B | $4.47B | ||||||
| Revlimid | — | — | — | $3.90B | ||||||
| Reyataz | $2.74B | $2.09B | — | — | ||||||
| Sustiva Franchise | $3.20B | $2.19B | — | — | ||||||
| Bulk Efavirenz Component Of Atripla | — | — | — | — | ||||||
| Avapro Avalide | — | — | — | — | ||||||
| Diabetes Alliance | — | — | — | — | ||||||
| Erbitux | — | — | — | — | ||||||
| Pomalyst/Imnovid | — | — | — | $966.00M | ||||||
| Empliciti | $450.00M | $693.00M | $741.00M | $1.07B | ||||||
| Onglyza Kombiglyze | — | — | — | — | ||||||
| Abraxane | — | — | — | $498.00M | ||||||
| Inrebic | — | — | — | $15.00M | ||||||
| Nulojix | — | — | — | — | ||||||
| Total | $59.00B | $68.53B | $67.68B | $78.44B |
In fiscal 2019, which ended December 31, 2019, the 11 revenue lines Bristol Myers Squibb Co reported in this breakdown added up to $78.44B. The revenue lines reported changed from fiscal 2018, so the total is not directly comparable with the $67.68B reported that year. Eliquis was the largest revenue line, at $23.79B or 30.3% of the total, followed by Opdivo ($21.61B, 27.6%) and Orencia ($8.93B, 11.4%). Together, the two largest revenue lines made up 57.9% of this total.
Compared with fiscal 2018, Eliquis grew the fastest, rising 23.2% to $23.79B. Every sizeable revenue line reported in both years grew. Because revenue lines were added or dropped between the two years, part of this reflects how Bristol Myers Squibb Co regrouped its reporting.
Mature & Other Brands (fiscal 2019), Revlimid (fiscal 2019), Pomalyst/Imnovid (fiscal 2019) and Abraxane (fiscal 2019) were first reported as separate revenue lines during this period. The table also keeps 14 revenue lines that Bristol Myers Squibb Co no longer reports, so earlier years can still be read on their original basis; use "Show 14 discontinued" beneath the table to see them. This breakdown covers 10 fiscal years between 2009 and 2019, as reported in Bristol Myers Squibb Co's annual filings.
Bristol Myers Squibb Co (BMY) breaks its revenue down by region and revenue line. In fiscal 2025, its largest region was United States, with $99.84B or 69.1% of the total, followed by International at $41.48B (28.7%).
United States was Bristol Myers Squibb Co's largest region in fiscal 2025, with $99.84B in revenue, 69.1% of the $144.58B reported across its 3 regions.
Ono was Bristol Myers Squibb Co's largest revenue line in fiscal 2014, with $339.00M in revenue, 52.6% of the $645.00M reported across its 2 revenue lines.
Of the Bristol Myers Squibb Co regions reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, Other grew the fastest, rising 9.1% from $2.99B to $3.26B.
Every figure is taken from Bristol Myers Squibb Co's annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by region covers fiscal 2009 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.